Amazon cover image
Image from Amazon.com

Cystic and idiopathic pulmonary fibrosis : risk factors, management and long-term health outcomes / Lorenzo Robertson, editor.

Contributor(s): Material type: TextTextSeries: Pulmonary and respiratory diseases and disorders seriesPublisher: New York : Nova Biomedical, [2016]Description: 1 online resourceContent type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781634855488
  • 1634855485
Subject(s): Genre/Form: Additional physical formats: Print version:: Cystic and idiopathic pulmonary fibrosisDDC classification:
  • 616.3/72 23
LOC classification:
  • RC858.C95
NLM classification:
  • WI 820
Online resources:
Contents:
CYSTIC AND IDIOPATHIC PULMONARY FIBROSIS RISK FACTORS, MANAGEMENT AND LONG-TERM HEALTH OUTCOMES ; CYSTIC AND IDIOPATHIC PULMONARY FIBROSIS RISK FACTORS, MANAGEMENT AND LONG-TERM HEALTH OUTCOMES ; CONTENTS ; PREFACE; Chapter 1 CLINICAL MANIFESTATIONS OF CYSTIC FIBROSIS AND THEIR MANAGEMENT ; Abstract; List of Abbreviations; Introduction; Epidemiology; Molecular Biology; CFTR Gene; CFTR Biosynthesis; Structure of CFTR; Overview of CFTR Function; Pathophysiology; Types of Mutations; Class I Mutations; Class II Mutations; Class III Mutations; Class IV Mutations; Class V Mutations
Class VI MutationsEffect of CFTR Dysfunction on Various Tissues; Sweat Glands; Lung and Small Airways; Paranasal Sinuses; Pancreas; Intestines; Liver and Gallbladder; Reproductive Tract; Bones; Other Organ Systems; Management; Clinical Features; Differential Diagnosis; Overview of Treatment; Treatment of Pulmonary Disease; Treatment of Gastrointestinal Disease; Treatment of Endocrine Abnormalities; Other Aspects of Treatment; Novel Treatment Strategies; Outcome Measures; Pulmonary Function Testing; Imaging-Based Measures; Sputum Biomarkers; Blood-Based Biomarkers; Potential Difference
Sweat Chloride TestPrognosis and Risk Factors; Conclusion; Conflict of Interests; References; Biographical Sketch; Chapter 2 LIVER DISEASE IN CYSTIC FIBROSIS: PREVALENCE, RISK FACTORS, AND OUTCOMES ; Abstract; Introduction; Objective; Methods; Screening for Liver Disease; Physical Examination; Liver Biochemistry Studies; Echographic Examination; Hepatobiliary Scintigraphy; Analysis of Clinical and CFTR Genotype Data; Statistic Analysis; Results; Discussion; Conclusion; References; Chapter 3 LUNG TRANSPLANTATION FOR CYSTIC FIBROSIS ; Abstract; Introduction
Selection of Patients for Lung TransplantationCriteria for Referral; Contraindications; Pre-Transplant Evaluation; Listing for Transplantation; Preparation for Transplantation; Surgical Issues and Technical Considerations; Post-Transplant Management; Peri-Operative Management and Complications; Delayed Onset and Chronic Complications; Post-Transplant Surveillance; Outcomes; Conclusion; References; Chapter 4 NEW CYSTIC FIBROSIS THERAPY ; Abstract; Introduction; Evolution of CF Therapy; Nutritional Management; Clinical Trials of Ivacaftor in Patients with the Gly551Asp CFTR Mutation
Clinical Trials of Ivacaftor in Patients with CFTR Mutation Other Than G551DTargeted Therapies for Patients with Phe508del CFTR Mutation; Targeted Therapies for Patients with Class I Mutation; Gene Therapy; Conclusion; References; Biographical Sketch; Chapter 5 DISTINCT PATTERNS OF PULMONARY INJURY AND FIBROSIS INDUCED BY INTRATRACHEAL AND SUBCUTANEOUS BLEOMYCIN IN THE MOUSE: RELEVANCE FOR DISTINCT FORMS OF HUMAN LUNG FIBROSIS ; Abstract; List of Abbreviations; Introduction; Results
Item type:
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Home library Collection Call number Materials specified Status Date due Barcode
Electronic-Books Electronic-Books OPJGU Sonepat- Campus E-Books EBSCO Available

Includes bibliographical references and index.

CYSTIC AND IDIOPATHIC PULMONARY FIBROSIS RISK FACTORS, MANAGEMENT AND LONG-TERM HEALTH OUTCOMES ; CYSTIC AND IDIOPATHIC PULMONARY FIBROSIS RISK FACTORS, MANAGEMENT AND LONG-TERM HEALTH OUTCOMES ; CONTENTS ; PREFACE; Chapter 1 CLINICAL MANIFESTATIONS OF CYSTIC FIBROSIS AND THEIR MANAGEMENT ; Abstract; List of Abbreviations; Introduction; Epidemiology; Molecular Biology; CFTR Gene; CFTR Biosynthesis; Structure of CFTR; Overview of CFTR Function; Pathophysiology; Types of Mutations; Class I Mutations; Class II Mutations; Class III Mutations; Class IV Mutations; Class V Mutations

Class VI MutationsEffect of CFTR Dysfunction on Various Tissues; Sweat Glands; Lung and Small Airways; Paranasal Sinuses; Pancreas; Intestines; Liver and Gallbladder; Reproductive Tract; Bones; Other Organ Systems; Management; Clinical Features; Differential Diagnosis; Overview of Treatment; Treatment of Pulmonary Disease; Treatment of Gastrointestinal Disease; Treatment of Endocrine Abnormalities; Other Aspects of Treatment; Novel Treatment Strategies; Outcome Measures; Pulmonary Function Testing; Imaging-Based Measures; Sputum Biomarkers; Blood-Based Biomarkers; Potential Difference

Sweat Chloride TestPrognosis and Risk Factors; Conclusion; Conflict of Interests; References; Biographical Sketch; Chapter 2 LIVER DISEASE IN CYSTIC FIBROSIS: PREVALENCE, RISK FACTORS, AND OUTCOMES ; Abstract; Introduction; Objective; Methods; Screening for Liver Disease; Physical Examination; Liver Biochemistry Studies; Echographic Examination; Hepatobiliary Scintigraphy; Analysis of Clinical and CFTR Genotype Data; Statistic Analysis; Results; Discussion; Conclusion; References; Chapter 3 LUNG TRANSPLANTATION FOR CYSTIC FIBROSIS ; Abstract; Introduction

Selection of Patients for Lung TransplantationCriteria for Referral; Contraindications; Pre-Transplant Evaluation; Listing for Transplantation; Preparation for Transplantation; Surgical Issues and Technical Considerations; Post-Transplant Management; Peri-Operative Management and Complications; Delayed Onset and Chronic Complications; Post-Transplant Surveillance; Outcomes; Conclusion; References; Chapter 4 NEW CYSTIC FIBROSIS THERAPY ; Abstract; Introduction; Evolution of CF Therapy; Nutritional Management; Clinical Trials of Ivacaftor in Patients with the Gly551Asp CFTR Mutation

Clinical Trials of Ivacaftor in Patients with CFTR Mutation Other Than G551DTargeted Therapies for Patients with Phe508del CFTR Mutation; Targeted Therapies for Patients with Class I Mutation; Gene Therapy; Conclusion; References; Biographical Sketch; Chapter 5 DISTINCT PATTERNS OF PULMONARY INJURY AND FIBROSIS INDUCED BY INTRATRACHEAL AND SUBCUTANEOUS BLEOMYCIN IN THE MOUSE: RELEVANCE FOR DISTINCT FORMS OF HUMAN LUNG FIBROSIS ; Abstract; List of Abbreviations; Introduction; Results

eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide

There are no comments on this title.

to post a comment.

O.P. Jindal Global University, Sonepat-Narela Road, Sonepat, Haryana (India) - 131001

Send your feedback to glus@jgu.edu.in

Hosted, Implemented & Customized by: BestBookBuddies   |   Maintained by: Global Library